CompletedPhase 2NCT01408914

Trial of High-Dose Rifampin in Patients With TB

Studying Tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Harvard University Faculty of Medicine
Principal Investigator
Carole D Mitnick, Sc.D
Harvard Medical School (HMS and HSDM)
Intervention
Higher-Dose Rifampin(drug)
Enrollment
180 enrolled
Eligibility
18-60 years · All sexes
Timeline
2013 – 2016

Study locations (4)

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID) · Sanofi · Harvard School of Public Health (HSPH) · Brigham and Women's Hospital · University of Liverpool · St George's, University of London · University of Florida · Socios en Salud

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01408914 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials